Glinton Hanover
YOU?
Author Swipe
View article: Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
-Supplementary Materials
View article: Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.
View article: Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S7: GO analysis of the BioID assay.
View article: Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
View article: Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
View article: Figure S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S4. A. Heatmap of the shRNA screen hits that are enriched in the top 15 GO processesgenerated using GSEA software. B. Gene Set Enrichment Analysis plots of the top 15 GOprocess for the shRNA screen data produced by GSEA software used …
View article: Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the …
View article: Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S6. EPHA2, c-MET and EGFR levels in human tumors.
View article: Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.
View article: Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precis…
View article: Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S1. The amino acid sequence of EPHA2 extracellular portion composed of ligand bindingdomain followed by sushi-like domain and two sequential fibronectin-like domains is highlyconserved among mammals.
View article: Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S6. EPHA2, c-MET and EGFR levels in human tumors.
View article: Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S6. EPHA2, c-MET and EGFR levels in human tumors.
View article: Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.
View article: Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S5: GO analysis of the shRNA screen in αEPHA2-Cond cells.
View article: Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
View article: Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the …
View article: Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
-Supplementary Materials
View article: Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precis…
View article: Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S6: Hits from the EPHA2 BioID assay.
View article: Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S7: GO analysis of the BioID assay.
View article: Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S1. The amino acid sequence of EPHA2 extracellular portion composed of ligand bindingdomain followed by sushi-like domain and two sequential fibronectin-like domains is highlyconserved among mammals.
View article: Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the …
View article: Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
View article: Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precis…
View article: Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
View article: Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S6: Hits from the EPHA2 BioID assay.
View article: Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S5: GO analysis of the shRNA screen in αEPHA2-Cond cells.
View article: Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
View article: Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Open
Fig. S1. The amino acid sequence of EPHA2 extracellular portion composed of ligand bindingdomain followed by sushi-like domain and two sequential fibronectin-like domains is highlyconserved among mammals.